Trials / Unknown
UnknownNCT03733327
BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT
Busulfan+ Cyclophosphamide+ Etoposide Conditioning Regimen for Primary Central Nervous System Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Nanfang Hospital, Southern Medical University · Academic / Other
- Sex
- All
- Age
- 14 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of BUCYE conditioning regimens in primary central nervous system lymphoma undergoing autologous hematopoietic stem cell transplantation.
Detailed description
The prognosis of patients with primary central nervous system lymphoma (PCNSL) is poor. Recent studies have demonstrated that autologous hematopoietic stem cell transplantation (auto-HSCT) could improve the prognosis of these patients. However, the optimal conditioning regimen of auto-HSCT remains unclear. In this study, the investigators evaluated the safety and efficacy of BUCYE conditioning regimens in PCNSL undergoing auto-HSCT.
Conditions
- Primary Central Nervous System Lymphoma
- Autologous Hematopoietic Stem Cell Transplantation
- Conditioning
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Busulfan (BU) | Busulfan was administered at 3.2 mg/kg/day on days-7 to -4. |
| DRUG | Cyclophosphamide (CY) | Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2. |
| DRUG | Etoposide (VP-16) | Etoposide was administered at 15 mg/kg/day on days -3 to -2. |
Timeline
- Start date
- 2018-11-01
- Primary completion
- 2021-10-01
- Completion
- 2021-10-01
- First posted
- 2018-11-07
- Last updated
- 2018-11-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03733327. Inclusion in this directory is not an endorsement.